A Study of Nopan Treatment of Acute Suicidality

Prof. Yoram Yovell60 enrolled

Overview

Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Suicidality

Interventions

NopanDRUG

Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)

PlaceboDRUG

Placebo in a manner similar to the active comparator

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * suicidal behavior or ideation (BSI\>6) Exclusion Criteria: * ECT history within the last month * psychotic features within the last 3 months * history of schizophrenia, substance or alcohol abuse within the last two years * benzodiazepine dependence within the last two years * any significant systemic illness or unstable medical condition which does not permit inclusion, according to the research physician * pregnant women * patients who currently suffer from severe impairment or severe dysfunction of liver, kidney, adrenal, gall, closed brain injury, urinary retention or respiratory system.

Locations (3)

Abarbanel MHC

Bat Yam, Israel

RECRUITING

Edith Wolfson Medical Center

Holon, Israel

RECRUITING

Brill Community Mental Health Center

Tel Aviv, Israel

RECRUITING

Outcomes

Primary Outcomes

Reduction in Suicidality as expressed by the score on the BSI

Time frame: 4 weeks

Secondary Outcomes

Reduction in depression as measured by the BDI

Time frame: 4 weeks

Central Contacts

Yoram Yovell, MD, PhD

CONTACT

972-4-8249910 isan@research.haifa.ac.il

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.